Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neuroblastoma: biology, prognosis, and treatment.
Park JR, Eggert A, Caron H. Park JR, et al. Pediatr Clin North Am. 2008 Feb;55(1):97-120, x. doi: 10.1016/j.pcl.2007.10.014. Pediatr Clin North Am. 2008. PMID: 18242317 Review.
Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group.
Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK; Children's Oncology Group. Park JR, et al. Pediatr Blood Cancer. 2009 Jan;52(1):44-50. doi: 10.1002/pbc.21784. Pediatr Blood Cancer. 2009. PMID: 18937318 Free PMC article. Clinical Trial.
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK. Wagner LM, et al. Among authors: park jr. J Clin Oncol. 2009 Mar 10;27(8):1290-6. doi: 10.1200/JCO.2008.18.5918. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171709 Free PMC article. Clinical Trial.
High-risk neuroblastoma: a therapy in evolution.
Fong A, Park JR. Fong A, et al. Among authors: park jr. Pediatr Hematol Oncol. 2009 Nov;26(8):539-48. doi: 10.3109/08880010903121173. Pediatr Hematol Oncol. 2009. PMID: 19954363 Review.
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. Bensimhon P, et al. Among authors: park jr. Pediatr Blood Cancer. 2010 Apr;54(4):596-602. doi: 10.1002/pbc.22344. Pediatr Blood Cancer. 2010. PMID: 20049927 Free PMC article. Clinical Trial.
Neuroblastoma: biology, prognosis, and treatment.
Park JR, Eggert A, Caron H. Park JR, et al. Hematol Oncol Clin North Am. 2010 Feb;24(1):65-86. doi: 10.1016/j.hoc.2009.11.011. Hematol Oncol Clin North Am. 2010. PMID: 20113896 Review.
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.
Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Minturn JE, et al. Among authors: park jr. Cancer Chemother Pharmacol. 2011 Oct;68(4):1057-65. doi: 10.1007/s00280-011-1581-4. Epub 2011 Feb 22. Cancer Chemother Pharmacol. 2011. PMID: 21340605 Free PMC article. Clinical Trial.
460 results